Good afternoon, ladies and gentlemen, and welcome to the Cajun Pharmacy Services Fourth Quarter Earnings Release Conference Call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question-and-answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. This call is being recorded on Wednesday, March 11, 2026. And I would like to turn the conference over to Ashley Stapton. Please go ahead.

Good afternoon. Thank you for participating in today's conference call. My name is Ashley Stockton, Vice President, Investor Relations for Guardian Pharmacy Services. I'm joined on today's call by Fred Burke, President and Chief Executive Officer, and David Morris, Chief Financial Officer. After the close today, Guardian posted its financial results for the quarter ended December 31, 2025. A copy of the press release is available on the company's Investor Relations website. Please note that today's discussion will include certain forward-looking statements that reflect our current assumptions and expectations, including those related to our future financial performance and industry and market conditions. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. We encourage you to review the information in today's press release, as well as in our annual report on Form 10-K to be filed with the SEC, including the specific risk factors and uncertainties discussed therein. We do not undertake any duty to update any forward-looking statements, which speak only as of the date they are made. On today's call, we also will use certain non-GAAP financial measures when discussing the company's financial performance and condition. You can find additional information on these non-GAAP measures and reconciliations to their most directly comparable GAAP financial measures in today's press release, which again is available on our Investor Relations website. And now, I will turn it over to Fred for commentary.

Thank you, Ashley, and good afternoon, everyone. We appreciate your continued interest as we review another very strong quarter and year for Guardian. Turning briefly to the fourth quarter, we delivered results that exceeded our expectations across the board, reflecting solid execution throughout the organization. David will walk through the quarterly details in more depth. What I would like to focus on today is our full-year 2025 performance, including our key financial results and major accomplishments. Looking back, 2025 was one of broad-based execution and disciplined investment, with results that were ahead of plan. Our annual performance was anchored by organic revenue growth of 13%, driven by new resident additions script growth and higher acuity acquisitions three of which were completed mid-year complemented our organic results and brought full year reported revenue growth to 18 percent adjusted EBITDA grew 27 percent year over year with margins expanding 50 basis points to 7.9 percent this increase These occurred even as we integrated acquisitions that remain early in their path to profitability, navigated a branded inhaler category headwind, which was an unintended consequence of the American Rescue Plan, and absorbed new public company costs. That performance reflects disciplined execution, operating leverage, and the scalability of our model. Importantly, this earnings strength translated directly into cash generation and balance sheet flexibility, allowing us to invest for continued growth while further strengthening our financial position. We continue to deploy capital toward acquisitions and greenfield startups in attractive markets while also investing in new data analytics capabilities. Even with these investments in growth, technology, and infrastructure, we increased our cash balance by approximately $60 million, reflecting the strong cash-generating nature of our model. Lastly, we delivered a full-year return on equity of 27%. This performance underscores our disciplined approach to capital allocation. Our financial results ultimately reflect the operational and clinical value we deliver every day. From that perspective, 2025 was a strong year clinically and reinforced the value Guardian brings to the broader healthcare network. Our pharmacists continue to play a critical role in medication management and care coordination. Through comprehensive medication reviews this year, our pharmacists performed more than 100,000 clinical interventions, benefiting approximately 74,000 residents. These interventions address serious risk, such as duplicate therapies and drug allergies, helping prevent adverse events. Through our proactive insurance optimization program, we helped residents achieve an estimated $56 million in cost savings, illustrating the tangible economic value our teams deliver every day. Our vaccine clinics administered over 120,000 vaccines during the third and fourth quarters, A 9% increase in script volumes for the full vaccine season with a material improvement in profitability year-over-year. In addition, we continued to invest in our customer service efforts. By way of example, we completed the rollout of our HIPAA-compliant secure messaging systems branded Guardian Hub and Guardian Note. this investment helps improve real-time visibility for facility partners in the prescription order status from intake to fulfillment to delivery enhancing service reliability and workflow efficiency importantly our impact is not anecdotal these outcomes are measured and tracked through our data and analytics platform clearly demonstrating our ability to to deliver differentiated clinical outcomes, reduce adverse events, and drive meaningful cost savings. In doing so, we deepen our partnerships across the care continuum and reinforce our clear and durable competitive advantage. Now, with 2025 in the rear view, I want to turn my focus to the future. And I'll start with the IRA, since that is one of the most significant shifts our industry has experienced in over a decade, impacting pricing, reimbursement dynamics, processes, and payments. In January, we announced that we expect to offset the anticipated EBITDA impact in 2026 6 from this policy change, an important milestone as we navigated the unintended consequences of the legislation. In addition to the pricing and reimbursement changes, the IRA also introduced a new operational complexity with the launch of the Medicare Transaction Facilitator, a government-run payment clearinghouse. We are closely monitoring operations in the early days of this new environment, which involves various third parties, to make sure the systems, processes, and pricing adjustments are functioning as intended. Our objective is to avoid disruption to customers, service levels, partner relationships, and importantly, cash flow. At the industry level, the IRA has created pressure across the long-term care pharmacy ecosystem. Within that context, we believe Guardian's scale, operating discipline, and local service model position us well to provide stability and consistent service as the industry works through this transition. These attributes are also becoming increasingly important in light of other changes in the industry. Stepping back, the long-term care pharmacy environment continues to evolve with ongoing consolidation at the facility level and increasing operational complexity. At the same time, demographic tailwinds are expected to accelerate. As the calendar turned to 2026, the first cohort of the Silver Tsunami entered their 80s, and with each successive year, the number of people in that cohort increases dramatically, which we anticipate will create an incremental tailwind. As occupancy rates rise, we believe operators will need to place greater emphasis on stability, consistency and efficient clinical and operational processes we believe both these dynamics favor pharmacy partners like Guardian who can help reduce the labor burden on facilities and reliably deliver increasingly sophisticated capabilities we have also seen recent industry developments including a bankruptcy filing by an institutional long-term care pharmacy we are monitoring developments, and as always, we are evaluating market opportunities through a disciplined strategic lens with a focus on aligning our current geographical presence, operating model, culture, and long-term objectives. With these changes in mind, we believe the need for dependable, high-quality pharmacy service is becoming increasingly important to facility operators. Our priority remains to continue supporting our partners with consistent, reliable execution. With that backdrop, let me turn to our outlook. When we provided guidance in mid-January, we did so earlier than usual to signal that our adjusted EBITDA growth trajectory remained intact despite the IRA. At that time, we did not yet have full visibility into our final 2025 results. With the year now complete, we are updating our outlook to reflect what we now can see with greater clarity. As always, we frame guidance on an annual basis grounded in what we can forecast with confidence, especially in a period of industry change. We also distinguish carefully between structural improvements in our business and favorable dynamics that can vary quarter to quarter. Reflecting the durable portion of our recent outperformance and applying our low double-digit growth framework, we are raising our 2026 adjusted EBITDA guidance to $120 to $124 million. This outlook reflects the ongoing drivers of our business and reinforces our confidence in the company's continued growth momentum. We are maintaining our current revenue forecast of $1.4 to $1.42 billion as new pricing flows through from the IRA. In summary, we delivered consistent outperformance this year and exited with solid momentum that we expect to continue into 2026 as we focus on driving durable growth, expanding margins as we scale, and investing to support long-term value creation for our shareholders. Most importantly, I want to recognize the people at Guardian, the pulse behind our organization and the reason we continue to deliver. Thank you for your continued focus and efforts. With that, I'll turn the call over to David to walk through the financial details.

Thank you, Fred, and good afternoon, everyone. I'm pleased to review another strong quarter in which we deliver results ahead of our expectations. We ended the quarter serving over 205,000 residents, an increase of 10% year-over-year. Script volume grew 14% year-over-year, while revenue increased 17% year-over-year to $397.6 million, a top 12% organic growth. Gross profit rose 27% to $85.5 million, with gross margins expanding to 21.5% from 19.8% a year ago. Performance in the quarter reflects structural improvements, including stronger vaccine economics, improved contribution from acquisitions and greenfield startups, as well as continued success with our plan optimization initiatives. Let me start with vaccines. Vaccine script volumes were up 3% year over year in line with their expectations as some volume was pulled into the third quarter. More importantly, we saw an increase in profitability due to better vaccine purchasing and reimbursement. We also benefited from contributions from Greenfield locations, which are ramping efficiently and performing ahead of our initial expectations. Acquisitions also contributed to the outperformance as we implemented purchasing and reimbursement programs sooner than anticipated in our Pacific Northwest additions. Both locations also began onboarding national accounts earlier than is typical. Our greenfield startup and acquisitions made over the last two years as a group continue to dampen our overall margin by approximately 90 basis points. We also continue to see success from our plan optimization initiatives, which helped to increase our Medicare Part D mix within the portfolio, supporting better coverage and lower out-of-pocket costs for residents, plus improved reimbursement for us. In addition to the structural improvements, a portion of our upside in our gross margin was due to favorable pay-or dynamics and other quarter-to-quarter variability. While incorporated in our results, we do not forecast this continuing in our outlook. Moving down the income statement, adjusted SG&A was 13% of revenue versus 13.7% in the year-ago period. This reflects increasing scale efficiencies and improved labor leverage. DNA was consistent with the third quarter at $5.7 million. Stock-based compensation declined to approximately $1 million as we sunset the pre-IPO equity program. Adjusted EBITDA increased 53% year-over-year to $39.5 million, with margins expanding to 9.9%, reflecting the operational drivers I just outlined, along with the favorable variability noted earlier. Adjusted EPS came in at 37 cents a share. Turning to the balance sheet, the business continues to generate strong cash flow. During the quarter, we increased our cash balance to $66 million, up from $36 million at the end of the third quarter and $5 million at the end of 2024, highlighting our strong cash conversion rate of approximately 60%. We achieved this annual performance by continuing to invest for future growth, funding four new acquisitions and ongoing investments in several de novo greenfield startups from operating cash flow. To recap, our Wichita acquisition earlier this year and our Montana purchase later in the year expanded our operational footprint in key growth markets. We also added locations in Washington and Oregon mid-year, establishing a platform in the Pacific Northwest to better serve our national accounts. Building on that momentum, we are actively engaged in discussions with several pharmacies that we believe would be strong additions to our platform and an excellent cultural fit. Importantly, we remain in a very strong financial position with ample liquidity and internally generated cash flow to support these investments. Now let me walk you through how we're approaching our outlook for 2026. For the full year 2025, we delivered adjusted EBITDA of $115 million ahead of our most recent guidance range of $104 to $106 million and well above our original outlook of $99 million at the midpoint issued a year ago. As noted, four-quarter results included favorable variability, which we do not forecast continuing in our 2026 outlook. We also forecast acuity remaining at current levels. We view the adjusted EBITDA run rate of our business as we exit 2025 to be approximately $110 million. Building on that foundation and reflecting low double-digit growth from the durable drivers of our business, we're raising our 2026 adjusted EBITDA guidance to a range of $120 to $124 We're maintaining our current revenue forecast of $1.4 to $1.42 billion as the new pricing impact flows through from the IRA. As always, our outlook does not include the impact of future acquisitions. On a more granular basis, we expect the quarterly distribution of revenue and adjusted EBITDA as a percentage of the full year to be very similar to what we experienced in 2025. We will continue to see seasonality from vaccine contributions weighted toward the fourth quarter. DNA should be roughly $21 million for the year. Following the additional annual LTIP grants we issued in March 1 this year, we expect our stock-based compensation expense to step up to a quarterly run rate of approximately $3 million. Our effective tax rate is expected to normalize to approximately 26% in 2026. Looking beyond 2026, additional branded drug negotiations under the IRA will take effect in 2027 and 2028. We expect these impacts to be much smaller than the 2026 revenue impact, approximately a $65 million revenue headwind in 2027. As a result, we view these incremental impacts as manageable within our existing growth framework. In closing, we're pleased with how we finished the year. The fourth quarter capped a period of consistent execution and reinforced the durability of our operating model, positioned us well as we move into 2026. I also want to echo Fred's recognition of our employees, whose dedication drives our performance every day. Operator will now open the line for questions.

Thank you. Ladies and gentlemen, we will now begin the question-and-answer session. Should you have a question, please press star followed by the one on your telephone keypad. And should you wish to cancel your request, please press star followed by the two. If you are using a speakerphone, please lift the handset before pressing any keys. One moment, please, for your first question. Thank you. And your first question comes in the line of John Ransom from Raymond James. Please go ahead.

Good afternoon. Can you hear me? Loud and clear. Hello. I've been having some tech issues, David. So, just still trying to process the 4QB, I know there are some non-recurring things in there, but could you help us understand, like, what's durable, what was vaccine, what's non-recurring in the quarter?

John, you're breaking up just a little bit, but we're guiding to our run rate we talked about as we ended the year, approximately $110 billion of EBITDA. And the variability with all the change going on in the industry that we had in the fourth quarter, we're not projecting that into our base. And we mentioned the things that that related to. They're always puts and takes with our PBM payors. Typically, they net out. In Q4, we had a net positive. So that's one thing that's not in our base that we're continuing. Also, increasing acuity is not in our base. So those are the main drivers that are not in there.

So did the vaccine program contribute more this year than last year? I know it was a big success for you last year.

It continued to be significant, both revenue and profit-wise in Q4, but we had some improvement on the reimbursement side and the buy side. So it continued to grow with our business, but the margins did expand slightly.

And then just kind of taking a step back, I know you're probably tired of talking about the IRA negotiations, But I think one thing you mentioned before was you wanted to take this opportunity to try to balance the profit contribution between generics and branded to better reflect, you know, the fact that 90% of your script volume is generic. So maybe just kind of talk about at a high level, knowing you've got contract confidentially, but just a high level, what were you able to get done from a contracting standpoint to kind of better balance the two profit streams?

John, that's something we've been working on even before. IRA, and we make progress for several payors in 2025, you mentioned that 92% of our prescriptions that we dispense are generic, and I can say we're moving forward in a positive manner from aligning the gross margin dollars with that activity.

And then just finally, you had mentioned a stat a couple of calls ago that if you were to run everything at your mature margin. You've got a number of pharmacies now that are not at mature margin. Is that gap between potential margin and realized margin still what it was a couple of quarters ago?

It's a little bit more. We said 80 basis points last quarter. It was closer to 90 basis points in Q4, and that's the investment we're making for future locations and future accretive profitability.

Okay, that's it for me.

Thank you, John.

Thank you. And your next question comes from the line of David McDonald from True West. Please go ahead.

Yeah, good afternoon, everyone. Just a couple. I wanted to follow up on John's first question a little bit. Guys, just on the vaccine program, you highlighted a couple of things that improved profitability. I think you used the word materially. It didn't sound like any of those wouldn't be durable. Hey, are we thinking about that correctly? And then, B, you know, if we look at the better assumed margins in the 2026 guidance, you know, is there one or two things that kind of stands out in terms of what is incrementally driving those margins better than your prior expectations?

Yeah, let me start with the vaccine clinic. The profitability, and it was slightly improved in 25 versus 24, that's durable and will, you know, continue into 2026. And I think the midpoint of our new guidance is 8.6% is our adjusted EBITDA margin. And, David, that's really a factor of us continuing our year-on-year adjusted EBITDA growth rate in the low double digits while the revenues remain flattish. And the function of that will take us to midpoint adjusted EBITDA of about 8.6%. So we will see it go up.

And I'll pipe in, Dave, to add to what David's comments that, yes, the vaccine clinics have contributed materially to our Q4, and we would expect to see that in next year. It is part of the business.

And then, guys, just, you know, you mentioned some of the competitive dynamics in terms of, you know, a competitor out there. Can you just, you know, spend a minute on the opportunity around either, you know, share gain with some struggling competitors, potentially, you know, more aggressive on the M&A side or, you know, pace of green fields around some of the areas where you see, you know, maybe some outsized opportunities, just, you know, some of the disruption that some of the competitors are seeing or certainly at least one, you know, just some of the opportunities that that potentially raises for you guys.

It's a very difficult topic to expand on because we are participating in the bankruptcy process, but all the things you mentioned could potentially represent opportunities for us as we move forward and that process is complete.

And then, guys, just one last one. You mentioned labor as, you know, a benefit on the margin side. You know, obviously, as you scale, you get increased efficiencies. But, you know, on the labor side, are you seeing both efficiencies and some improvement in just labor inflation? Or is that more just, you know, as you get bigger, you're able to better leverage the labor force that you've got in place?

Dave, it's more of the latter, that the scale, wherever the scale, the existing platform, that scale is labor and that's more of what's driving the efficiencies.

Okay.

Thanks very much. That's all for me.

Thank you.

Thank you. Once again, that is Tara N1 to ask a question. And your next question comes from the line of Fred Schumacher from Stevens. Please go ahead.

Hey, good afternoon. Maybe just kind of maybe touching on the prepared remarks around the faster ramp up in the recently acquired facilities. As you kind of think about, you know, the large and regional accounts and kind of what that constitutes as far as the current residents face, maybe just kind of any framing on the, you know, the remaining opportunity on that front. And then also, I guess, you know, since ALF is your core end market, you know, there's been a lot of activity around divestitures or kind of disposition of operations from, you know, certain large regional accounts of yours. And maybe if there's kind of any impact that you see on that front or, you know, maybe any color on how you ensure continuity of service and continue to cover the residents while, you know, these operational changes going in the background.

I'll take the latter question and then hand it to David. Yes, as the industry undergoes consolidation, I'm speaking now of the assisted living operators, our core market segment, we believe that it provides us with opportunity. And in fact, one example that you, I'm assuming that you're citing, was they ended up being exactly that. We have maintained service at all the facilities that we were serving, and it's given us an opportunity to meet new operating groups and show to them what we can do. So on balance, those types of dislocations represent, in our opinion, an opportunity for us.

And then, Raj, on your first question, we mentioned that we were able to integrate and achieve scale earlier with the platforms, particularly that we close in Pacific Northwest, and they vary. We talk a lot about, on average, it takes four years, plus or minus, to bring acquisitions up and achieve the synergies. Things like, you know, operating systems, purchasing platforms, national accounts that can come on sooner or not later, they impact these businesses. And in the Pacific Northwest, we were able to execute on some of these things earlier.

Got it. And then maybe kind of thinking about the M&A pipeline. I think, you know, there's been estimates where 60% of long-term care pharmacies are at risk of shutting down given cash flow constraints and IRA pricing. And so as we kind of think about, you know, your strategy and, you know, what's available out there from an M&A standpoint in terms of your typical tuck-in, are you seeing a kind of, you know, a buyer's market per se on that front? And then relative to the kind of inherent opportunity post-acquisition, Does that still remain the same, or do you see kind of more upside based on the assets that are coming into the market?

Good question, Raj. I want to start by emphasizing that we believe very strongly in being supportive of our industry, and the last thing we want to see are our industry colleagues under duress. And that's why we've worked so hard and diligently with our trade group, the SEPC, to mitigate the effects of the various changes that are occurring on the policy front, you know, from D.C. That said, it's early days. we're going through the first implementation of this IRA which as I mentioned in my remarks introduces new processes reimbursements procedures cash flow etc etc and I'm hopeful that our industry colleagues can manage their way through it potentially could impact our opportunity on the M&A front and we certainly would welcome that opportunity with light-mounted operators, but too early to call on that for sure right now at the minute, but something we'll be watching as we move forward.

You know, Raj, and as it relates to our pipeline, we have a robust pipeline at 25. It continues to be robust in 26. And as Fred said, as we're navigating all these industry changes, we're going to continue to take a disciplined approach. We seek like-minded operators in territories that we want to expand into. So I think we're adopting a very consistent approach as to what we've had the last couple of years.

Got it.

Thank you. And there are no further questions at this time. Ladies and gentlemen, this concludes today's call. Thank you for participating. You may all disconnect.